Quick Comparison

LL-37Pentosan Polysulfate
Half-Life4-6 hours (varies by tissue environment)20-27 hours
Typical DosageResearch: 50-200 mcg subcutaneous once daily. Topical formulations also used for wound healing applications. No standardized clinical dosing established.Oral (Elmiron): 100 mg three times daily for interstitial cystitis. Injectable (compounding): 2-3 mg/kg subcutaneous or intramuscular once or twice weekly for 4-8 weeks for joint applications.
AdministrationSubcutaneous injection or topicalOral capsule or subcutaneous/intramuscular injection
Research Papers30 papers11 papers
Categories

Mechanism of Action

LL-37

LL-37 is the only cathelicidin-derived antimicrobial peptide in humans, cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophil granules. It functions as a critical component of the innate immune system's first line of defense, with both direct antimicrobial activity and sophisticated immunomodulatory signaling.

The direct antimicrobial mechanism relies on LL-37's amphipathic alpha-helical structure — one face is positively charged (cationic) while the other is hydrophobic. The cationic face electrostatically attracts the negatively charged phospholipid headgroups of bacterial membranes (which differ from mammalian membranes in their lipid composition and charge distribution). Once bound, the hydrophobic face inserts into the lipid bilayer, creating pores or disrupting membrane integrity through a 'carpet' or 'toroidal pore' mechanism. This physical membrane disruption kills bacteria, fungi, and enveloped viruses rapidly and is difficult for microbes to develop resistance against, unlike conventional antibiotics that target specific enzymes.

The immunomodulatory functions are equally important. LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL1) activation, recruiting immune cells to infection sites. It promotes macrophage phagocytosis and enhances the killing capacity of neutrophil extracellular traps (NETs). Critically, LL-37 neutralizes bacterial lipopolysaccharide (LPS/endotoxin), preventing the cytokine storm that leads to sepsis. It also stimulates angiogenesis through VEGF upregulation and promotes wound re-epithelialization by activating epidermal growth factor receptor (EGFR) transactivation. LL-37 production is upregulated by vitamin D (which is why vitamin D status affects innate immunity), and its expression is found in skin, airways, the gastrointestinal tract, and virtually all epithelial barrier tissues.

Pentosan Polysulfate

Pentosan Polysulfate (PPS) is a semi-synthetic, sulfated polysaccharide derived from beechwood hemicellulose (xylan). Its structure consists of a xylose backbone with sulfate ester groups at positions 2 and 3, giving it a high negative charge density similar to heparin and endogenous glycosaminoglycans like heparan sulfate. This polyanionic character is central to its multiple mechanisms of action.

In joint and cartilage repair, PPS stimulates chondrocyte proteoglycan synthesis — the production of aggrecan and other proteoglycans that form the hydrated gel matrix of articular cartilage. Proteoglycans are responsible for cartilage's compressive resilience and water retention, and their loss is a hallmark of osteoarthritis. PPS also inhibits matrix metalloproteinases (MMPs), particularly MMP-3, MMP-9, and MMP-13, which are the enzymes responsible for cartilage matrix degradation in osteoarthritis. By simultaneously promoting matrix synthesis and inhibiting matrix breakdown, PPS shifts the balance toward cartilage repair. Additionally, PPS improves synovial fluid viscosity by stimulating hyaluronic acid synthesis from synoviocytes, partially restoring the lubrication and shock-absorbing properties lost in arthritic joints.

PPS has several additional pharmacological properties. It inhibits complement activation (particularly the alternative pathway), reducing inflammatory damage to joint tissues. It has fibrinolytic activity — promoting the dissolution of fibrin deposits that can form in inflamed synovial tissue and contribute to joint adhesions. It inhibits certain lipases and has lipid-clearing properties. In its FDA-approved indication (interstitial cystitis), PPS is thought to replenish the damaged glycosaminoglycan layer lining the bladder epithelium, restoring the protective barrier against urine irritants. The recent FDA warning about retinal pigmentary maculopathy with long-term oral use (affecting approximately 1 in 4 long-term users) appears to be related to accumulation of PPS metabolites in the retinal pigment epithelium, where they may disrupt lysosomal function and pigment recycling.

Risks & Safety

LL-37

Common

injection site inflammation, local redness and swelling.

Serious

at high doses it can worsen inflammation instead of calming it; may trigger or worsen autoimmune conditions like psoriasis, lupus, or atherosclerosis.

Rare

body-wide inflammatory response, allergic reactions. Effects depend on dose — low doses calm inflammation, high doses can increase it.

Pentosan Polysulfate

Common

bruising, injection site pain, headache, nausea, diarrhea, hair loss (oral).

Serious

retinal pigmentary maculopathy with long-term oral use (FDA warning — unique, potentially irreversible vision damage), liver damage (rare).

Rare

low platelet count, severe allergic reactions. Regular eye exams recommended with oral use beyond 2 years.

Full Profiles